文献速递糖尿病肥胖与代谢综合征

脂联素、胰岛素敏感性与β细胞功能及TODAY研究中治疗失败率的种族/民族差异

Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY.
PubMed 文献 · Diabetes Care · 2016-11-01

TODAY研究显示,二甲双胍联合罗格列酮、单用二甲双胍及二甲双胍联合生活方式三种治疗合计的血糖失败率在非西班牙裔黑人(NHB)为52.8%,高于非西班牙裔白人(NHW)的36.6%和西班牙裔(H)的45.0%。本研究分析三个种族/民族组治疗相关的脂联素、胰岛素敏感性和β细胞功能随时间的变化,以探讨差异机制。

要点

  • 基线时NHB的高分子量脂联素(HMWA)显著低于NHW和H。
  • 治疗前6个月HMWA增幅在NHB为17.3%,低于NHW的33.7%和H的29.9%。
  • HMWA升高与血糖失败风险降低相关,风险比(HR)为0.61,P<0.0001。

核心结论

  • HMWA是2型糖尿病青少年治疗反应的可靠生物标志物。
  • NHB治疗相关的HMWA增幅较NHW和H低约50%,可能解释TODAY中NHB治疗失败率更高的种族/民族差异。

研究设计与样本

  • TODAY研究为治疗试验,参与者定期接受口服葡萄糖耐量试验以测定胰岛素敏感性、C肽指数和口服处置指数(oDI),并测量总脂联素和高分子量脂联素(HMWA)。

主要发现

  • 基线时NHB的HMWA显著低于NHW和H。
  • 治疗前6个月HMWA总体增幅在NHB为17.3%,NHW为33.7%,H为29.9%。
  • 三个种族/民族组合并分析中,HMWA升高与血糖失败减少相关(风险比0.61,P<0.0001),各人群单独分析亦相关。
  • 无论种族/民族,治疗失败者的HMWA随时间均显著低于未失败者。
  • 三个种族/民族组间在胰岛素敏感性、C肽指数和oDI的治疗相关时间变化上无差异。

关键数值与推荐

  • 三种治疗合计的血糖失败率:NHB为52.8%,NHW为36.6%,H为45.0%。
  • 单用二甲双胍在NHB中的效果低于NHW,NHW低于H。
  • HMWA升高与血糖失败的风险比为0.61(P<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined-metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle-were higher in non-Hispanic blacks (NHB; 52.8%) versus non-Hispanic whites (NHW; 36.6%) and Hispanics (H; 45.0%). Moreover, metformin alone was less effective in NHB versus NHW versus H youth. This study describes treatment-associated changes in adiponectin, insulin sensitivity, and β-cell function over time among the three racial/ethnic groups to understand potential mechanism(s) responsible for this racial/ethnic disparity. RESEARCH DESIGN AND METHODS: TODAY participants underwent periodic oral glucose tolerance tests to determine insulin sensitivity, C-peptide index, and oral disposition index (oDI), with measurements of total and high-molecular-weight adiponectin (HMWA). RESULTS: At baseline NHB had significantly lower HMWA than NHW and H and exhibited a significantly smaller increase (17.3% vs. 33.7% vs. 29.9%, respectively) during the first 6 months overall. Increases in HMWA were associated with reductions in glycemic failure in the three racial/ethnic groups combined (hazard ratio 0.61, P < 0.0001) and in each race/ethnicity separately. Over time, HMWA was significantly lower in those who failed versus did not fail treatment, irrespective of race/ethnicity. There were no differences in treatment-associated temporal changes in insulin sensitivity, C-peptide index, and oDI among the three racial/ethnic groups. CONCLUSIONS: HMWA is a reliable biomarker of treatment response in youth with type 2 diabetes. The diminutive treatment-associated increase in HMWA in NHB (∼50% lower) compared with NHW and H may explain the observed racial/ethnic disparity with higher therapeutic failure rates in NHB in TODAY.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Arslanian S, El Ghormli L, Bacha F, et al. Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. Diabetes Care. 2016. PMID: 27803118. doi:10.2337/dc16-0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。